Pritam Sadhukhan

Student of Cancer Biology, Postdoctoral Fellow, Johns Hopkins University

[Pritam Sadhukhan @pritam_bi]

Aiming for combinatorial drug therapy can potentailly improve treatment efficacy, reduce drug resistance, and minimize side effects in UCB treatment.

My sincere thanks to all the collaborators!!

[Journal of Clinical Investigation @jclinicalinvest]

How can we make bladder cancer treatments more effective?
@pritam_bi & team @HopkinsMedicine show YAP1 signaling promotes immune evasion & find the YAP1 inhibitor verteporfin with immune checkpoints as a strategy to increase therapeutic efficacy in mice.
https://t.co/HSsSbBWC5E

[Pritam Sadhukhan @pritam_bi]

📢 Call for Papers!

I’m serving as Guest Editor for a new Special Issue in IJMS on Cancer immunology.

We aim to foster collaboration and highlight cutting-edge research in this field.

Submit here:
https://t.co/TiGKJXgGUi

#CallForPapers #MolecularBiology #OpenAccess

[Luca Arecco, MD @Lucarecco]

🚭 From 1970–2022, declining U.S. smoking rates prevented 3.9 million lung cancer deaths:
👨 2.3M men
👩 1.6M women

This saved 76 million years of life!
Nearly half of all avoided cancer deaths were from lung cancer prevention.
@CACancerJournal @OncoAlert

[Dr. Ron DePinho @RonDePinho]

Fantastic @Cancer_Cell paper by @IamLinghua @MDAndersonNews revealing new biology in cancer-associated fibroblasts. https://t.co/y2Tixij8Zv

[Sandra Misale @Sandra_Misale]

Fresh out of press! 🧬🔬We are happy to share our latest work published in @CancerDiscovery! https://t.co/sbNgJyDDz9 A thread🧵 Please, Enjoy and share! #CancerResearch, #PrecisionOncology #CancerTherapeutics

[Tom Powles @tompowles1]

B7H3 (CD276) is an immune checkpoint and is widely expressed on tumor cell. The B7H3/TROP2 ADC shows significant activity especially in small cell lung cancer and head and neck cancer. Toxicity reflects the payload. B7H3 levels by IHC didn’t correlate with outcome @NatureMedicine

[Cancer Cell @Cancer_Cell]

Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche https://t.co/K5lpbRRKU7

[Sougata Sadhukhan, Ph.D. @bioacousticist]

🐺 Exciting PhD opportunity in #Wildlife! As a guide, I’m looking for motivated students interested preferably in #quantitativeecology, application of #ecology, or #bioacoustics. Let’s make a difference in wildlife conservation #PhDAdmissions #WildlifeConservation #wildlifeindia

[Elisa Agostinetto @ElisaAgostinett]

Now out in @CellRepMed our review on emerging treatments for HER2+ #breastcancer

We discuss how survival improvements in this disease set a high bar for new drug development and the need to explore new ways to overcome resistance mechanisms

@OncoAlert

https://t.co/HpZgo4NiDk

[Vedang Murthy @VedangMurthy]

Patience and Perseverance from the entire GU team at @TataMemorial.
The Multicentre phase 3 RCT of Adj RT post RCIC+ Chemo accrued the last patient (n=153)
Took 8 years but we got there in the end. Phew!
Interested in the early results?
Coming soon at a conference near you!

[Johns Hopkins University @JohnsHopkins]

#BmoreStrong

[Andrea Apolo, M.D. @apolo_andrea]

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer https://t.co/kVdir19drK

[Cancer Immunology Research @CIR_AACR]

Read the new priority brief—
Intracellular K+ Limits #Tcell Exhaustion and Preserves Antitumor Function, by Camille Collier et al.
https://t.co/rVqd6pIlUE
@OHSUsurgery

[Elizabeth McKenna @ElizSMcKenna]

Don’t miss “Cancer in 2023” in @CD_AACR, an excerpt from the @AACR #CancerProgressReport 👇🏻

[Miriam Merad, MD, PhD @MiriamMerad]

Very excited by our results @Nature showing that IL4R signaling is strongly enriched in myeloid cells that infiltrate mice and lung cancer lesions https://t.co/Nnjc7ue96y

[Andrea Apolo, M.D. @apolo_andrea]

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma | NEJM https://t.co/wqMHq443Oa

[@gulleyj1 @gulleyj1]

Honored to work with such an incredible team! And such a great project!

[Manisha Bhattacharya @ManishaDrB]

Nice to see some @vahsrd cross-pollination with @UREssien bringing his #pharmacoequity concept from a.fib to cancer at #ASCOQLTY23!

[Cancer Immunology Research @CIR_AACR]

New for the October issue—
ANXA1 Promotes Tumor #ImmuneEvasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers, by Ding Xiao, Ting Zeng, Wei Zhuang, Zhi-Qiang Xiao et al.
https://t.co/Gw8hrUt6qu
#CancerImmunology

[Brian Rini, MD @brian_rini]

Constant TKI is NOT necessary in IO/TKI regimens. We need to prioritize strategies to de-escalate therapy for better QOL and possibly delaying resistance. Congrats to @DrIacovelli and the team for this important work.